Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program
Administration for Strategic Preparedness and Response.
(2023).
Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.
U.S. Department of Health and Human Services.
This guide is intended to provide direction as the U.S. Government (USG) prepares to wind down the current distribution of USG-procured COVID-19 therapeutics and transitions the COVID-19 Oral Antiviral (OAV) treatments (nirmatrelvir packaged with ritonavir [Paxlovid] and molnupiravir [Lagevrio]) to the commercial market. This guide aims to help jurisdictions and providers (1) plan for the transition away from USG ordering; (2) understand the impact of this transition on ordering mechanism; (3) understand how to manage inventory of USG distributed OAV products, including continued reporting requirements for remaining USG inventory; and (4) provide summary information about programs to provide access for uninsured and underinsured individuals once COVID-19 OAVs become commercially available. T
Favorite:
Login to rate, favorite, and comments
on the article
Comments
0
Toggle Open/Close
You must Login to add a comment
- This item doesn't have any comments